|
1.
|
|
6 p, 2.1 MB |
MR imaging findings in primary spinal cord glioblastoma
/
Ferrante, Paolo (Hospital Universitari Vall d'Hebron) ;
Mora, Juan Andres (Fundación Universitaria Sanitas, Clinica Reina Sofia) ;
Salazar, Lourdes (Hospital Universitari Vall d'Hebron) ;
Sáez, Elena Martínez (Hospital Universitari Vall d'Hebron) ;
Auger, Cristina (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Rovira, Alex (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Universitat Autònoma de Barcelona
Spinal cord glioblastoma is a rare disease, with an aggressive course and a poor prognosis. We describe magnetic resonance imaging (MRI) findings, in 3 adult cases of biopsy-confirmed glioblastoma. Conventional MRI findings were unclear with regard to the differential diagnosis between this rare tumor and other more common spinal cord lesions, including less aggressive tumors such as ependymoma or pilocytic astrocytoma, abscesses or tumefactive demyelinating lesions. [...]
2020 -  10.1016/j.radcr.2020.10.043
Radiology Case Reports, Vol. 16 (november 2020) , p. 72-77
|
|
|
2.
|
|
7 p, 314.9 KB |
Epithelial-Mesenchymal Transition in the Resistance to Somatostatin Receptor Ligands in Acromegaly
/
Gil, Joan (Institut Germans Trias i Pujol) ;
Jordà, Mireia (Institut Germans Trias i Pujol) ;
Soldevila, Berta (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Puig Domingo, Manuel (Universitat Autònoma de Barcelona. Departament de Medicina)
Epithelial-mesenchymal transition (EMT) is a dynamic process by which epithelial cells loss their phenotype and acquire mesenchymal traits, including increased migratory and invasive capacities. EMT is involved in physiological processes, such as embryogenesis and wound healing, and in pathological processes such as cancer, playing a pivotal role in tumor progression and metastasis. [...]
2021 - 10.3389/fendo.2021.646210
Frontiers in Endocrinology, Vol. 12 (march 2021)
|
|
|
3.
|
|
11 p, 2.6 MB |
Development of adaptive immune effector therapies in solid tumors
/
Comoli, P. (Cell Factory and Pediatric Hematology Oncology. Fondazione IRCCS Policlinico San Matteo) ;
Chabannon, C. (Institut Paoli-Calmettes. Aix-Marseille University. INSERM CBT 1409. Centre for Clinical Investigation in Biotherapy) ;
Koehl, U. (Institute of Cellular Therapeutics. Hannover Medical School) ;
Lanza, F. (Hematology and Stem Cell Transplant. Romagna Transplant Network) ;
Urbano Ispizua, Álvaro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Hudecek, M. (University Hospital Würzburg) ;
Ruggeri, A. (Ospedale Pediatrico Bambino Gesù (Roma, Itàlia)) ;
Secondino, S. (Università degli Studi di Pavia. Dipartimento di Medicina Interna e Terapia Medica) ;
Bonini, C. (University Vita-Salute San Raffaele) ;
Pedrazzoli, P. (Università degli Studi di Pavia. Dipartimento di Medicina Interna e Terapia Medica) ;
Universitat Autònoma de Barcelona
State-of-the-art treatment strategies have drastically ameliorated the outcome of patients affected by cancer. However, resistant and recurrent solid tumors are generally nonresponsive to conventional therapies. [...]
2019 - 10.1093/annonc/mdz285
Annals of oncology, Vol. 30 Núm. 11 (november 2019) , p. 1740-1750
|
|
|
4.
|
|
8 p, 252.0 KB |
Is There A Role for Limited Parotid Resections for Primary Malignant Parotid Tumors?
/
Quer, Miquel (Universitat Autònoma de Barcelona. Departament de Cirurgia) ;
Olsen, Kerry D. (Mayo Clinic. Department of Otorhinolaryngology) ;
Silver, Carl E. (University of Arizona College of Medicine. Department of Surgery) ;
Hamoir, Marc (St Luc University Hospital and King Albert II Cancer Institute. Department of Head and Neck Surgery) ;
Mäkitie, Antti A. (University of Helsinki. Faculty of Medicine) ;
Rodrigo, Juan P. (Hospital Universitario Central de Asturias) ;
Vander Poorten, Vincent (University Hospitals Leuven) ;
Takes, Robert P. (Radboud University Medical Center) ;
Hellquist, Henrik (University of Algarve. Department of Biomedical Sciences and Medicine) ;
García Lorenzo, Jacinto (Universitat Autònoma de Barcelona. Departament de Cirurgia) ;
Guntinas-Lichius, Orlando Jena University Hospital ;
de Bree, Remco (University Medical Center Utrecht) ;
Suárez, Carlos (Instituto de Investigación Sanitaria del Principado de Asturias) ;
Kowalski, Luiz P. (Centro de Tratamento e Pesquisa Hospital do Cancer A.C. Camargo) ;
Vartanian, José G. (Hospital do Cancer A.C. Camargo) ;
Sanabria, Alvaro (Universidad de Antioquia. Department of Surgery) ;
Shaha, Ashok R. (Memorial Sloan Kettering Cancer Center) ;
Zbären, Peter (Universitätsspital Bern. Department of Otorhinolaryngology-Head and Neck Surgery) ;
Rinaldo, Alessandra (University of Udine. School of Medicine) ;
Ferlito, Alfio (International Head and Neck Scientific Group)
Background: Lateral or total parotidectomy are the standard surgical treatmentsfor malignant parotid tumors. However, some authors have proposed a more limited procedure. (2) Methods: We performed a review of the literature on this topic. [...]
2020 - 10.3390/surgeries1010002
Surgeries, Vol. 1 Núm. 1 (2020) , p. 2
|
|
|
5.
|
|
15 p, 1.9 MB |
Silencing of adaptor protein 32 reduces / receptors expression and impairs gastrointestinal stromal tumors growth
/
Serrano-Candelas, Eva (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Ainsua-Enrich, Erola (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Navinés-Ferrer, Arnau (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Rodrigues, Paulo (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
García-Valverde, Alfonso (Vall d'Hebron Institut d'Oncologia) ;
Bazzocco, Sarah (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
García-Valverde, Alfonso (Vall d'Hebron Institut d'Oncologia) ;
Macaya, Irati (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
García-Valverde, Alfonso (Vall d'Hebron Institut d'Oncologia) ;
Arribas, Joaquín (Universitat Autònoma de Barcelona) ;
Serrano, César (Hospital Universitari Vall d'Hebron) ;
Sayós, Joan (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Arango, Diego (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Martin, Margarita (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Gastrointestinal stromal tumors (s) represent about 80% of the mesenchymal neoplasms of the gastrointestinal tract. Most s contain oncogenic (85%) or (5%) receptors. The kinase inhibitor imatinib mesylate is the preferential treatment for these tumors; however, the development of drug resistance has highlighted the need for novel therapeutic strategies. [...]
2018 - 10.1002/1878-0261.12332
Molecular Oncology, Vol. 12 (june 2018) , p. 1383-1397
|
|
|
6.
|
|
12 p, 435.5 KB |
Phase 1 study of capmatinib in MET-positive solid tumor patients : Dose escalation and expansion of selected cohorts
/
Bang, Yung-Jue (Seoul National University College of Medicine) ;
Su, Wu-Chou (National Cheng Kung University Hospital) ;
Schuler, Martin (University Duisburg-Essen and German Cancer Consortium (DKTK)) ;
Nam, Do-Hyun (Samsung Medical Center) ;
Lim, Wan Teck (National Cancer Centre) ;
Bauer, Todd M. (PLLC) ;
Azaro, Analia (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Poon, Ronnie Tung Ping (Queen Mary Hospital) ;
Hong, David (University of Texas/MD Anderson Cancer Center) ;
Lin, Chia-Chi (National Taiwan University Hospital) ;
Akimov, Mikhail (Novartis Pharma AG) ;
Ghebremariam, Samson (Novartis Pharmaceuticals Corporation) ;
Zhao, Sylvia (China Novartis Institutes for BioMedical Research) ;
Giovannini, Monica (Novartis Pharmaceuticals Corporation) ;
Ma, Brigette (The Chinese University of Hong Kong)
Capmatinib is an oral, ATP-competitive, and highly potent, type 1b MET inhibitor. Herein, we report phase 1 dose-escalation results for capmatinib in advanced MET-positive solid tumor patients and dose expansion in advanced non-lung tumors. [...]
2019 - 10.1111/cas.14254
Cancer Science, Vol. 111 (december 2019) , p. 536-547
|
|
|
7.
|
|
12 p, 2.4 MB |
Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib
/
Jiménez-Fonseca, Paula (Medical Oncology Department, Hospital Universitario Central de Asturias) ;
Martín, Miguel Navarro (Medical Oncology Department, Hospital Universitario de Salamanca, IBSAL) ;
Carmona-Bayonas, Alberto (Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, UMU, IMIB) ;
Calvo, Alfonso (Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada) ;
Fernández-Mateos, Javier (Complejo Asistencial Universitario de Salamanca. Instituto de Investigación Biomédica de Salamanca) ;
Redrado, Miriam (IDISNA and Program in Solid Tumors and Biomarkers, Center for Applied Medical Research (CIMA), Department of Histology and Pathology, University of Navarra, Pamplona) ;
Capdevila Castillón, Jaume (Hospital Universitari Vall d'Hebron) ;
Lago, Nieves Martínez (Medical Oncology Department, Hospital Universitario de A Coruña) ;
Lacasta, Adelaida (Medical Oncology Department, Hospital Universitario Donostia) ;
Muñarriz, Javier (Medical Oncology Department, Hospital General Universitario de Castellón) ;
Segura, Ángel (Hospital Universitari i Politècnic La Fe de Valencia) ;
Fuster, Josep (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Barón, Francisco (Medical Oncology Department, Hospital Universitario de Santiago de Compostela) ;
Llanos, Marta (Hospital Universitario de Canarias (La Laguna)) ;
Serrano, Raquel (Hospital Universitario Reina Sofía (Córdoba, Espanya)) ;
Castillo, Alfredo (Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain) ;
Cruz Hernández, Juan Jesús (Medical Oncology Department, Hospital Universitario de Salamanca, IBSAL, Salamanca, Spain) ;
Grande, Enrique (Medical Oncology Department, MD Anderson Cancer Center) ;
Universitat Autònoma de Barcelona
Several circulating biomarkers and single nucleotide polymorphisms (SNPs) have been correlated with efficacy and tolerability to antiangiogenic agents. These associations remain unexplored in well-differentiated, metastatic pancreatic neuroendocrine tumors treated with the multitargeted tyrosine kinase inhibitor sunitinib. [...]
2018 - 10.18632/oncotarget.26380
Oncotarget, Vol. 9 (december 2018) , p. 36894-36905
|
|
|
8.
|
|
13 p, 2.9 MB |
Genomic profiling of NETs : A comprehensive analysis of the RADIANT trials
/
Yao, James (University of Texas MD Anderson Cancer Center) ;
Garg, Amit (Novartis Institutes for Biomedical Research) ;
Chen, David (Novartis Pharmaceuticals Corporation) ;
Capdevila Castillón, Jaume (Vall d'Hebron Institut d'Oncologia) ;
Engstrom, Paul (Fox Chase Cancer Center) ;
Pommier, Rodney (Oregon Health and Science University) ;
Van Cutsem, Eric (University Hospitals Gasthuisberg/Leuven. KU Leuven) ;
Singh, Simron (Odette Cancer Center. Sunnybrook Health Sciences Center) ;
Fazio, Nicola (European Institute of Oncology) ;
He, Wei (Novartis Pharmaceuticals Corporation) ;
Riester, Markus (Novartis Institutes for Biomedical Research) ;
Patel, Parul (Novartis Pharmaceuticals Corporation) ;
Voi, Maurizio (Novartis Pharmaceuticals Corporation) ;
Morrissey, Michael (Novartis Institutes for Biomedical Research) ;
Pavel, Marianne (University of Erlangen-Nuremberg) ;
Helmut Kulke, Matthew. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Universitat Autònoma de Barcelona
Neuroendocrine tumors (NETs) have historically been subcategorized according to histologic features and the site of anatomic origin. Here, we characterize the genomic alterations in patients enrolled in three phase 3 clinical trials of NET of different anatomic origins and assess the potential correlation with clinical outcomes. [...]
2018 - 10.1530/ERC-18-0332
Endocrine-Related Cancer, Vol. 26 Núm. 4 (2018), p. 391-403
|
|
|
9.
|
|
|
10.
|
|
13 p, 501.3 KB |
A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function
/
Azaro, Analía (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Rodón, Jordi (Hospital Universitari Vall d'Hebron) ;
Machiels, Jean-Pascal (Institut Roi Albert II (Bèlgica). Department of Medical Oncology) ;
Rottey, Sylvie (Universitair Ziekenhuis Gent) ;
Damian, Silvia (National Cancer Institute of Milan) ;
Baird, Richard (Early Phase Clinical Trials Team, Department of Oncology, University of Cambridge, Cambridge, UK) ;
Garcia-Corbacho, Javier (Early Phase Clinical Trials Team, Department of Oncology, University of Cambridge, Cambridge, UK) ;
Mathijssen, Ron H. J. (Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands) ;
Clot, Pierre-François (Sanofi, Chilly-Mazarin, France) ;
Wack, Claudine (Sanofi, Chilly-Mazarin, France) ;
Shen, Liji (Sanofi, Bridgewater, NJ USA) ;
de Jonge, Maja J. A. (Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands)
Limited data are available on cabazitaxel pharmacokinetics in patients with renal impairment. This open-label, multicenter study assessed cabazitaxel in patients with advanced solid tumors and normal or impaired renal function. [...]
2016 - 10.1007/s00280-016-3175-7
Cancer Chemotherapy and Pharmacology, Vol. 78 (october 2016) , p. 1185-1197
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
